MUSE Drug Patent Profile

When do Muse patents expire, and when can generic versions of Muse launch?

Muse is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in MUSE is alprostadil. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Muse

A generic version of MUSE was approved as alprostadil by HIKMA on January 20^th, 1998.

Summary for MUSE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MUSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-001	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-004	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-002	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996		DISCN	Yes	No

International Patents for MUSE

See the table below for patents covering MUSE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0791199
South Africa	8906681
Denmark	175560
Germany	69130529
South Korea	0169950
World Intellectual Property Organization (WIPO)	9002545

Investment Scenario and Fundamentals Analysis for MUSE

Last updated: February 3, 2026

What Is MUSE and What Is Its Market Position?

MUSE (Alprostadil), marketed as intracavernosal injection therapy, is used for erectile dysfunction (ED). It provides a less invasive alternative to penile implants, with a market dependence on the prevalence of ED, aging populations, and patient preferences.

Market Size and Commercial Potential

In 2022, the global ED treatment market was valued at approximately $4.4 billion. Projections estimate it will grow at a compound annual growth rate (CAGR) of 6% through 2030, reaching around $7.0 billion. MUSE, as a branded intracavernosal therapy, captures a significant share—estimated at 15-20% of the ED treatment market, depending on regional dynamics.

Key market drivers:

• Aging demographic (men over 50)
• Increasing awareness and diagnosis of ED
• Preference for localized, non-oral therapies among some patient subsets

Market challenges:

• Competition from oral PDE5 inhibitors (e.g., sildenafil)
• Patient reluctance due to injection discomfort
• Regulatory environment and reimbursement policies

Regulatory Status and Patent Landscape

MUSE is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). Its patent protections have largely expired or will do so within the next 5 years, opening markets to generic competition.

Patent expiry timeline:

• Original patents expired around 2018-2020
• No significant recent patents have been granted specifically for MUSE formulations, which suggests looming generic entry

Regulatory stability:

• Current approval remains in place in key markets such as the U.S., EU, and Japan, but market exclusivity diminishes as generics enter.

Financial Fundamentals

MUSE’s revenue streams primarily depend on market penetration, pricing, and competition dynamics.

Revenue estimates:

• In 2022, U.S. sales approximated $200 million, with global sales near $250 million.
• Post-patent expiry, generic prices could reduce revenues by 50-70%.

Cost structure:

• Manufacturing costs are moderate, with a significant portion allocated to distribution and marketing.
• Margins are high (~80%) pre-generic, but expected to decline as generic competition intensifies over the next 3-5 years.

Profitability outlook:

• Revenue decline projected post-2023 due to patent expiry.
• Companies investing in differentiation strategies (e.g., new formulations) might offset revenue loss temporarily.

Competitive Landscape and Alternatives

Key competitors include:

• Oral PDE5 inhibitors (sildenafil, tadalafil): market leader
• Other injectable therapies (e.g., alprostadil suppositories)
• Emerging technologies: gene therapy, regenerative medicine

Threat of generic MUSE-based products will compress pricing and sales volume.

R&D and Pipeline Considerations

The pipeline for ED treatments includes novel oral agents and non-invasive therapies. Limited innovation from MUSE’s parent companies in this space may make it vulnerable unless new formulations or expanded indications are developed.

Market Entry and Investment Risks

• Patent expiration reduces exclusivity
• Growing generic competition pressures prices and margins
• Market saturation in mature markets
• Regulatory hurdles for new formulations or delivery mechanisms
• Slow adoption among patients sensitive to injection therapies

Strategic Recommendations for Investors

• Monitor patent litigation and patent extensions
• Evaluate pipeline developments for new device or formulation innovations
• Assess regional market penetration potential post-generic entry
• Consider partnerships with generic manufacturers once patent cliff approaches
• Diversify investments into broader ED market segments, including emerging therapies

Key Takeaways

• MUSE operates in a mature, high-margin niche with steady demand driven by demographic trends.
• Patent expiry diminishes its competitive moat starting around 2023.
• Core revenues will decline unless offset by new formulations, indications, or market expansion.
• Competition from generics is imminent, pressuring prices and profitability.
• Investment upside hinges on innovation, new patent protections, or market differentiation strategies.

FAQs

1. When will generic MUSE products enter the market?
Generic versions are expected to launch between 2023 and 2025, following patent expirations in key territories.

2. How does MUSE compare to oral ED therapies in terms of market share?
MUSE holds about 15-20% of the ED treatment market, primarily among patients who cannot tolerate or prefer not to take oral medications.

3. What are the primary barriers to new entry in the MUSE market?
Patent protections, regulatory approvals for new formulations, and established clinician/patient preferences limit immediate competition.

4. Are there opportunities for companies to extend the lifecycle of MUSE?
Yes. Developing long-acting formulations, combination therapies, or new delivery devices can mitigate revenue decline.

5. How susceptible is MUSE to pricing pressure post-patent expiry?
Highly susceptible. Generic competition could lead to a 50-70% reduction in retail prices within a few years of patent expiry.

References

1. MarketsandMarkets. Erectile Dysfunction Market, 2022.
2. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations, 2022.
3. GlobalData. Erectile Dysfunction Treatment Market Analysis, 2023.
4. IMS Health. Pharmaceutical Market Data, 2022.